In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Izun Pharmaceuticals Corp., of New York, expanded its ongoing Phase II trial assessing the effect of IZN-6N4, on oral mucositis (OM) to two additional medical centers, Memorial Sloan Kettering Cancer Center and Beth Israel Medical Center, a component of the Continuum Cancer Centers of New York

Celsus Therapeutics plc, of New York, reported interim results from the first cohort of its Phase II trial of MRX-6, a non-steroidal, anti-inflammatory cream, for allergic contact dermatitis

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation

Bristol-Myers Squibb Co. (BMS), of New York, disclosed results from a 12-month subgroup analysis of a National Institutes of Health, open-label, long-term research study of metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported positive topline results from AUGMENT COPD, the second six-month pivotal Phase III trial evaluating the efficacy and safety of investigational fixed-dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair (Genuairn outside the U.S.) inhaler

Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpoint

GlycoMimetics partnered GMI-1070, a synthetic glycomimetic molecule designed to inhibit all three selectin types, in a worldwide agreement with Pfizer Inc., of New York, in 2011. (See BioWorld Today, Oct. 12, 2011

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair

Kythera Biopharmaceuticals Inc., of New York, reported that MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at the Aesthetic Meeting 2013 in New York

Secondary objectives are safety and tolerability, dyspnea, fluid overload, blood pressure, diuretic dose and New York Heart Association classification

The data were presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York...Viralytics Ltd., of Sydney, Australia, presented a summary of the CALM Phase II trial with Cavatak for melanoma at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York

Ohr Pharmaceutical Inc., of New York, said a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia did not meet the primary endpoint of weight gain, but the 18 patients who completed the treatment protocol achieved stable body weight, body fat and muscle mass with a significant increase in appetite (p = 0.001

Pfizer Inc., of New York, said the REMINDER trial of Inspra (eplerenone) showed statistically significant risk reductions in the primary composite efficacy endpoint, defined as time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) BioWorld Today | Tuesday, March 12, 2013